A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier
Open Access
- 4 April 2016
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 126 (5), 1717-1733
- https://doi.org/10.1172/jci76207
Abstract
The blood-brain barrier (BBB) protects the brain from toxic substances within the peripheral circulation. It maintains brain homeostasis and is a hurdle for drug delivery to the CNS to treat neurodegenerative diseases, including Alzheimer’s disease and brain tumors. The drug efflux transporter P-glycoprotein (P-gp) is highly expressed on brain endothelial cells and blocks the entry of most drugs delivered to the brain. Here, we show that activation of the A2A adenosine receptor (AR) with an FDA-approved A2A AR agonist (Lexiscan) rapidly and potently decreased P-gp expression and function in a time-dependent and reversible manner. We demonstrate that downmodulation of P-gp expression and function coincided with chemotherapeutic drug accumulation in brains of WT mice and in primary mouse and human brain endothelial cells, which serve as in vitro BBB models. Lexiscan also potently downregulated the expression of BCRP1, an efflux transporter that is highly expressed in the CNS vasculature and other tissues. Finally, we determined that multiple pathways, including MMP9 cleavage and ubiquitinylation, mediated P-gp downmodulation. Based on these data, we propose that A2A AR activation on BBB endothelial cells offers a therapeutic window that can be fine-tuned for drug delivery to the brain and has potential as a CNS drug-delivery technology.Keywords
This publication has 63 references indexed in Scilit:
- Adenosine receptors and membrane microdomainsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrierNature Protocols, 2010
- Lipid Rafts, Caveolae, and Their EndocytosisPublished by Elsevier BV ,2010
- Structure of a multidrug transporterNature Biotechnology, 2009
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Membrane rafts and caveolae in cardiovascular signalingCurrent Opinion in Nephrology and Hypertension, 2009
- Adenosine receptors: therapeutic aspects for inflammatory and immune diseasesNature Reviews Drug Discovery, 2008
- CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences of the United States of America, 2008
- P-Glycoprotein is not present in mitochondrial membranesExperimental Cell Research, 2007